Equities

SAGE Therapeutics Inc

SAGE Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)5.13
  • Today's Change0.28 / 5.77%
  • Shares traded665.36k
  • 1 Year change-73.60%
  • Beta0.8651
Data delayed at least 15 minutes, as of Nov 22 2024 20:49 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments7531,2721,742
Total Receivables, Net891419
Total Inventory1.50----
Prepaid expenses255140
Other current assets, total1.33----
Total current assets8691,3371,801
Property, plant & equipment, net6.381319
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets6.554.774.25
Total assets8821,3561,825
LIABILITIES
Accounts payable101910
Accrued expenses647066
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total8.59108.89
Total current liabilities839985
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total04.5911
Total liabilities8310496
SHAREHOLDERS EQUITY
Common stock0.010.010.01
Additional paid-in capital3,3703,2913,227
Retained earnings (accumulated deficit)(2570)(2028)(1495)
Treasury stock - common(0.4)(0.4)(0.4)
Unrealized gain (loss)------
Other equity, total(0.81)(10)(2.66)
Total equity8001,2531,729
Total liabilities & shareholders' equity8821,3561,825
Total common shares outstanding606059
Treasury shares - common primary issue0.000.000.00
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.